Background {#Sec1}
==========

Chronic spontaneous urticaria (CSU) is a complex, systemic disease with a multifactorial etiopathogenesis associated with autoimmune and inflammatory phenomena \[[@CR1]--[@CR3]\].

It has been hypothesized that CSU is associated with a T helper cell 17 (Th17)---mediated immune response \[[@CR4], [@CR5]\], which is characterized by production of interleukin 17 (IL-17). IL-17 is linked to pathogenesis of inflammatory/autoimmune diseases \[[@CR6], [@CR7]\].

The pro-inflammatory cytokine plays an important role in synthesis of many mediators, including IL-6, IL-8, IL-1β and TNF-α \[[@CR6], [@CR8]\], which may reflect the inflammatory state in CSU \[[@CR2], [@CR4], [@CR5]\].

Serum C reactive protein (CRP)---the best marker of acute phase response and IL-17 concentrations, may be associated with CSU activity \[[@CR2], [@CR5]\]. It has been suggested that IL-17-CRP signaling may play a role in chronic inflammatory conditions \[[@CR9]\], although, its regulation and function in CSU have remained unclear. Therefore, the aim of this study was to determine the relationship between circulating concentrations of IL-17 and CRP in CSU patients.

Methods {#Sec2}
=======

52 CSU patients (14 men and 38 women; median age: 38 years, range: 24--50) with a median disease duration of 2.5 years were enrolled in the study.

The patients underwent the following tests and procedures: routine laboratory tests, stool (for parasites and *H. pylori*), antinuclear and antithyroid microsomal antibodies, thyroid function, chest X-ray and abdominal ultrasonography, hepatitis serology, autologous serum skin test (ASST) \[[@CR10]\]. Additionally, dental, gynecological and ENT consultations were performed.

Urticaria activity score according to EAACI/GALEN/EDF guidelines was estimated during four days and on the blood sampling day and graded as follows: mild (0--8), moderate (9--16) and severe (17--24). The study comprised 28 patients with mild CSU and 24 patients with moderate-severe symptoms.

H1-antihistamine drugs were withdrawn at least 4 days before blood sampling. None of the patients had been taking immunosuppressants or any other drugs, for at least 8 weeks before the study.

The control group comprised 21 sex-, age- and BMI (\<30) matched the healthy subjects.

The Ethics Committee of the Medical University of Silesia approved of the study and written, informed consent was obtained from all the subjects participating.

Blood collection {#Sec3}
----------------

Blood samples were taken on fasting, from elbow veins using tubes with anticoagulant. Plasma obtained by centrifugation were stored at −85 °C until the tests were performed.

Assay of interleukin-17 (IL-17) {#Sec4}
-------------------------------

Concentrations of IL-17 in plasma samples were measured by ELISA method using commercially available kits (Quantikine Human CXCL8/IL-8 ELISA kit from R&D Systems, MN, USA) according to manufacturers' detailed instructions. The variance coefficients for intra-assay and inter-assay were below 8 and 10% respectively. Sensitivity of the kit is 15 pg/ml.

CRP assay {#Sec5}
---------

Serum C-reactive protein (CRP) concentrations were measured using Roche/Hitachi cobas c system. Normal lab ranges: lower than 5.0 mg/l.

Statistical analysis {#Sec6}
--------------------

The obtained results were presented with the use of basic parameters of descriptive statistics. Normal distribution of data was measured using Shapiro--Wilk's test. Independent data between two groups of patients with CSU and the controls were compared using non-parametric U Mann--Whitney test. Independent data between three groups of patients with mildCSU, moderate-severe CSU and the controls were compared using non-parametric ANOVA rang Kruskal--Wallis's test. The Spearman's rank test was used for correlations. The p \< 0.05 was considered statistically significant. Calculations were performed with STATISTICA for Windows 10.0 software (StatSoft, Cracow, Poland).

Results {#Sec7}
=======

Plasma IL-17 concentration {#Sec8}
--------------------------

Plasma concentrations of IL-17 were significantly higher in CSU patients as compared with the healthy subjects \[median and quartile range/min--max: 21.97 (20.92--24.98/18.85--62.73) vs. 19.88 (18.85--20.92/17.82--59.16) pg/ml, p \< 0.001; Fig. [1](#Fig1){ref-type="fig"}\].Fig. 1Plasma IL-17 concentration in chronic spontaneous urticaria (CSU) patients with different disease activity and in the healthy subjects. CSU vs. controls, p \< 0.001; moderate-severe CSU patients and mild CSU vs. controls, p \< 0.005; mild CSU vs. moderate-severe CSU, p \> 0.05

IL-17 plasma concentrations were significantly higher in moderate-severe and mild CSU patients as compared with the healthy subjects \[median and quartile range/min--max: 22.49 (20.92--24.08/18.85--62.73) and 21.97 (20.92--23.55/19.28--48.60) vs. 19.88 (18.85--20.92/17.82--59.16) pg/ml, p \< 0.005\]. Concentrations of IL-17 in mild CSU patients did not differ significantly versus moderate-severe CSU patients \[median and quartile range/min--max: 21.97 (20.92--23.55/19.28--48.60) vs. 22.49 (20.92--24.08/18.85--62.73) pg/ml, p \> 0.05; Fig. [1](#Fig1){ref-type="fig"}\].

No significant differences in IL-17 concentrations between ASST(+) and ASST(−) CSU patients (selected according to the similar UAS) were observed.

Serum CRP concentration {#Sec9}
-----------------------

Serum CRP concentrations were significantly higher in CSU patients as compared with the healthy subjects \[median and quartile range/min--max: 3.8 (1.30--9.20/0.70--46.90) vs. 0.4 (0.20--0.40/0.10--0.60) mg/l, p \< 0.001\]. In addition, there were significant differences in serum CRP concentration between CSU patients with mild, moderate-severe symptoms and the healthy subjects \[median and quartile range/min--max: 1.4 (20.92--23.55/19.28--48.60) vs. 9.8 (20.92--24.08/18.85--62.73) vs. 0.4 (0.20--0.40/0.10--0.60) mg/l, respectively; p \< 0.001; Fig. [2](#Fig2){ref-type="fig"}\].Fig. 2CRP concentration in serum of chronic spontaneous urticaria (CSU) patients and in the healthy subjects. CSU vs. controls, p \< 0.001; mild CSU vs. moderate-severe CSU vs. controls, p \< 0.001

Correlation between values of CRP and IL-17 in patients with CSU {#Sec10}
----------------------------------------------------------------

CRP did not correlate significantly with IL-17 (r = 0.12, p = 0.41).

Discussion {#Sec11}
==========

In our study, plasma IL-17 concentrations were significantly higher in CSU patients as compared with the healthy subjects. In addition, there were significant differences in IL-17 concentrations between CSU patients with mild, moderate-severe symptoms and the healthy subjects. However, IL-17 values did not show significant differences between the groups of mild and moderate-severe disease. Atwa et al. reported increased IL-17 serum concentrations in CSU patients that paralleled disease severity and ASST response \[[@CR5]\]. In addition, there is some convincing evidence to prove that acute phase activation is associated with CSU activity/severity and may be involved in pathogenesis of the disease \[[@CR2]\]. Based on association between acute phase response and IL-17, we addressed the question whether increased IL-17 and CRP are related to each other.

It has been demonstrated that IL-17 can stimulate CRP and IL-6 expression, suggesting that the cross-talk between IL-17 and CRP/IL-6 may further amplify an inflammatory cascade \[[@CR9], [@CR11]\].

It is known that IL-6-CRP signaling plays an important role in CSU. Interestingly, it has been suggested that IL-17 stimulates CRP expression independently of IL-1 and IL-6. However, IL-17 may act in synergy with IL-6, which potentiates IL-17-mediated CRP expression. \[[@CR9]\].

The link between IL-6 and CRP has been confirmed in CSU \[[@CR2]\]. In the present study, we did not observe any association between CRP and IL-17 concentrations in CSU patients, contrary to the expectations.

The lack of correlation between IL-17 and CRP suggests, that increased IL-17 concentration cannot be regarded as a simple reflection of acute phase activation. IL-17 seems to be related to a wider spectrum of immune/inflammatory responses and provides independent information from the acute phase response in CSU. CRP concentration is increased in CSU patients and it may reflect the disease activity/severity. However, mild urticarial processes can result in only slight elevation (within normal range) of the acute phase response marker.

Th17 cells and their signature cytokine---IL-17 play a key role in initiation and maintenance of autoimmune and inflammatory processes in different diseases, leading to secretion of several inflammatory factors and autoantibody production \[[@CR7], [@CR12]\].

The source of IL-17 in CSU is unclear. Elevated IL-17 is likely to result from activation of different cells involved in urticarial processes, especially mast cells \[[@CR13]\]. It has been demonstrated that mast cells primarily MC~TC~ cells, are the most numerous cells containing IL-17 in human skin \[[@CR13]\]. These cells are able to produce IL-17 upon stimulation with various stimuli, including TNF-alpha and C5a \[[@CR13]\]. IL-17 is produced by many other cell types including lymphocytes, neutrophils \[[@CR14], [@CR15]\].

All of these factors are upregulated and may play role in pathogenesis of immune-inflammatory response in CSU \[[@CR1], [@CR16]\].

The current study confirms that circulating IL-17 concentrations are increased in CSU patients \[[@CR4], [@CR5]\]. Similar observations have been made in various inflammatory and autoimmune diseases providing the rationale for development of the anti-IL-17A monoclonal antibody \[[@CR6], [@CR14]\]. Therefore, it seems that biological agents targeting IL-17A signalling pathways may represent a potential approach for treating CSU.

Conclusions {#Sec12}
===========

The current finding confirms that circulating IL-17 concentration is increased in CSU patients and may represent an independent index of systemic inflammatory response, which is not related to increased CRP concentration.
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